30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: Stryker

$2,190MM, +3% (U.S. $1,441MM, +4%, ex-U.S. $749MM, +0.2%)

Reconstructive $969MM, +3% (U.S. +7%, ex-U.S. -2%)

  • Hips $308MM, +1% (U.S. +4%, ex-U.S. -2%)
  • Knees $345MM, -1% (U.S. -0.4%, ex-U.S. -2%)
  • Trauma/Extremities $266MM, +12% (U.S. +26%, ex-U.S. -1%)

Neurotechnology/Spine $397MM, +6% (U.S. +7%, ex-U.S. +4%)

  • Neurotechnology $221MM, +13% (U.S. +15%, ex-U.S. +10%)
  • Spine $176MM, -2% (U.S. flat, ex-U.S. -6%)

MedSurg Equipment $824MM, +1%

MedSurg includes patient handling and emergency medical equipment. Growth reflects constant currency and excludes acquisitions.

 

  • ~6% overall revenue arises from Emerging Markets
  • Completed acquisition of Trauson in China
  • Within Extremities, Foot/Ankle +50%
  • Joint Preservation (SportsMed, Implants + Biologics) +>50%
  • Cortoss growth in double-digits
  • Anticipates filing 510(k) for ShapeMatch custom cutting guides in 2Q
  • Continuing investment in GetAroundKnee campaign to support Triathlon
  • Launching Reverse Shoulder around mid-year
  • Estimates that ~10% of knee procedures use some type of custom cutting guide